World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
79
Citations
20619
World Ranking
1702
National Ranking
840

James W. Hodge publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where James W. Hodge sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 234 publications — 46th percentile

46% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

James W. Hodge D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where James W. Hodge sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 79 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

James W. Hodge is affiliated with the National Institutes of Health in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a focus on Oncology and Immunology as subfields. Other areas of study include Pulmonary and Respiratory Medicine, Genetics, and Surgery.

The scientist's work is concentrated on several main topics:

  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Immune cells in cancer
  • Sarcoma Diagnosis and Treatment
  • Head and Neck Surgical Oncology

Frequent coauthors collaborating with James W. Hodge include:

  • Kellsye P. Fabian
  • Michelle R. Padget
  • Jeffrey Schlom
  • Clint Allen
  • James L. Gulley

James W. Hodge has published extensively in several venues, with notable numbers of publications in the following journals and proceedings:

  • Journal for ImmunoTherapy of Cancer
  • Regular and Young Investigator Award Abstracts
  • Frontiers in Oncology
  • Cancer Immunology Research
  • Cancers

Selected recent papers by James W. Hodge include:

  • "Consensus guidelines for the definition, detection and interpretation of immunogenic cell death" (2020, Journal for ImmunoTherapy of Cancer)
  • "Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study" (2020, Clinical Cancer Research)
  • "PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations" (2020, Journal for ImmunoTherapy of Cancer)
  • "From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment" (2021, Frontiers in Oncology)
  • "The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy" (2021, Molecular Therapy - Oncolytics)

Best Publications

  • Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

    Eric A. Reits;James W Hodge;Carla A Herberts;Tom A M Groothuis

  • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Lorenzo Galluzzi;Ilio Vitale;Sarah Warren;Sandy Adjemian

  • Consensus guidelines for the detection of immunogenic cell death

    Oliver Kepp;Laura Senovilla;Ilio Vitale;Erika Vacchelli

  • Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

    Charlie T. Garnett;Claudia Palena;Mala Chakarborty;Kwong-Yok Tsang

  • Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy

    Mala Chakraborty;Scott I. Abrams;Kevin Camphausen;Kebin Liu

  • External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.

    Mala Chakraborty;Scott I. Abrams;C. Norman Coleman;Kevin Camphausen

  • Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

    Michael B. Bernstein;Sunil Krishnan;James W. Hodge;Joe Y. Chang

  • Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

    James L. Gulley;Philip M. Arlen;Anne Bastian;Steven Morin

  • Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

    John L. Marshall;James L. Gulley;Philip M. Arlen;Patricia K. Beetham

  • Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

    Abhishek D. Garg;Lorenzo Galluzzi;Lionel Apetoh;Lionel Apetoh;Thais Baert

  • Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

    Sofia R. Gameiro;Momodou L. Jammeh;Max M. Wattenberg;Kwong Y. Tsang

  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

    James L. Gulley;Philip M. Arlen;Ravi A. Madan;Kwong-Yok Tsang

  • A triad of costimulatory molecules synergize to amplify T-cell activation.

    James W. Hodge;Helen Sabzevari;Alicia Gómez Yafal;Linda Gritz

  • Chemotherapy‐induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death

    James W. Hodge;Charlie T. Garnett;Benedetto Farsaci;Claudia Palena

  • Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement

    Charlie T. Garnett;Jeffrey Schlom;James W. Hodge

  • Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

    James L. Gulley;Philip M. Arlen;Kwong-Yok Tsang;Junko Yokokawa

  • Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

    Ravi A Madan;Philip M Arlen;Mahsa Mohebtash;James W Hodge

  • Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

    James W. Hodge;Joanne P. McLaughlin;Judith A. Kantor;Jeffrey Schlom

  • Induction of Antitumor Immunity by Recombinant Vaccinia Viruses Expressing B7-1 or B7-2 Costimulatory Molecules

    James W. Hodge;Scott Abrams;Jeffrey Schlom;Judy A. Kantor

  • Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

    Erika J Lampert;Alexandra S Zimmer;Michelle R Padget;Ashley Cimino-Mathews

  • Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

    Sofia R. Gameiro;Momodou L. Jammeh;Max M. Wattenberg;Kwong Y. Tsang

Frequent Co-Authors

Jeffrey Schlom
Jeffrey Schlom National Institutes of Health
James L. Gulley
James L. Gulley National Institutes of Health
Kwong Y. Tsang
Kwong Y. Tsang National Institutes of Health
Philip M. Arlen
Philip M. Arlen National Institutes of Health
John W. Greiner
John W. Greiner National Institutes of Health
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
Massimo Fantini
Massimo Fantini Precision Biologics
Scott I. Abrams
Scott I. Abrams Roswell Park Cancer Institute
Soldano Ferrone
Soldano Ferrone Harvard University
Dennis Panicali
Dennis Panicali Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related online degrees can provide versatile career options in healthcare and research. Many students pivot towards nursing programs, which offer practical applications of immunological principles in patient care.

If you’re new to the field, consider online nursing programs for non nurses. These programs are designed to help individuals without a nursing background quickly enter the profession and build relevant skills.

For faster routes, accelerated nursing programs near me offer intensive coursework that compresses the traditional timeline for earning a Bachelor of Science in Nursing.

There are also options like the best easiest lpn programs to get into, which provide foundational nursing credentials and can be a stepping stone to advanced roles specializing in immunological care.

For those aiming to become advanced practitioners, seeking out the easiest fnp program can ease the path to becoming a Family Nurse Practitioner, where immunology knowledge is essential for managing patients with immune-related conditions.

Best Scientists Citing James W. Hodge

Trending Scientists